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Abstract
Streptococcus pneumoniae-related infections are a major cause of morbidity and mortality in people of all ages worldwide. Pneumococcal
vaccine development started in 1911 with a whole cell vaccine and more recently multivalent plain polysaccharide and polysaccharide
conjugate vaccines have been developed. The recent vaccines rely on capsular polysaccharide antigens to induce serotype-specific
immune responses. We summarize here the presentations on pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197
carrier protein) given during the integrated symposium organized and funded by Pfizer International Operations during the 22nd
European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 31 March to 3 April 2012, London, UK. A dramatic
reduction in the incidence of invasive pneumococcal diseases (IPD) due to vaccine serotypes (VST-IPD) has been reported since the
introduction of a hepta-valent pneumococcal conjugate vaccine (PCV7). An indirect (herd) effect has been demonstrated to be
associated with PCV7 infant vaccination programmes, with many studies reporting reductions in VST-IPD in populations that are not
eligible for PCV7 vaccination. Since 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) has been introduced into national
immunization programmes and results from early surveillance suggest that this vaccine also has an impact on the serotypes unique to
PCV13, as well as continuing to protect against the PCV7 serotypes. Data from a passive surveillance system in Europe in 2009, for
instance, showed that the highest incidence of IPD remains in those aged >65 years and in children <5 years. PCV13 has now been
licensed for vaccination of adults >50 years based on safety and immunogenicity data; an efficacy trial is being conducted. Regardless of
previous pneumococcal vaccination status, if the use of 23-valent polysaccharide is considered appropriate, it is recommended to give
PCV13 first. Novel immunization strategies remain the only practical means to reduce significantly the remaining global mortality and
morbidity due to S. pneumoniae in adults.
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Introduction
Streptococcus pneumoniae-related infections are a major cause
of morbidity and mortality in people of all ages worldwide [1].
The bacteria can cause invasive pneumococcal diseases (IPD),
such as bacteraemia and meningitis, non-invasive infections,
such as acute otitis media, sinusitis and mastoiditis, and
pneumonia, which can be either invasive (bacteraemic pneu-
monia) or non-invasive (non-bacteraemic pneumonia). Pneu-
monia acquired outside healthcare or extended care facilities is
known as community-acquired pneumonia (CAP) [2].
The clinical burden of IPD is bacteraemia, meningitis and
bacteraemic pneumonia. Establishing the burden of IPD
depends on laboratory-based surveillance. Although CAP is
more prevalent than IPD, it is difficult to estimate the clinical
burden of CAP attributable to S. pneumoniae. From the clinical
and microbiological points of view, there are several reasons
why this is so, including: (i) the heterogeneity of the clinical
picture associated with CAP; (ii) physicians often do not
request laboratory confirmation of their diagnosis; (iii) the
sub-optimal sensitivity of the current standard laboratory test,
blood culture, the sensitivity of which is further hindered by
frequent early antibiotic therapy during the initial stages of
illness and the polymicrobial nature of the infection; and finally,
(iv) the difficulty in obtaining detailed laboratory data and
clinical phenotyping particularly for patients in the community
setting (outpatient and home/office visits). These difficulties
are reflected, epidemiologically, in the wide variability of
incidence and mortality data reported in the literature for
adults over the last 20 years.
The age-specific incidence of IPD and pneumonia is highest
in the younger and older segments of the population, with a
rise in adults starting from about 50 years of age [3,4]. Before
the introduction of pneumococcal conjugate vaccine (PCV) in
infant vaccination programmes, IPD incidence was high in
young children. For example, it was estimated that in the USA
there were 65 000 cases of IPD annually, with >16 000 (25%)
occurring in children <5 years old [5]. In Europe, before PCV
introduction, the reported IPD incidence varied in children
<2 years from 1.7 per 100 000 in Sweden to 174 per 100 000
in Spain [6]. These differences in incidence rates might be
explained by different surveillance systems and blood culture
practices [7]. Globally, pneumococcal disease is estimated to
be responsible for >800 000 deaths a year in children <5 years
old [8], most of these being attributed to pneumonia. In
addition, 90% of pneumococcal deaths among children
<5 years old in the ten countries with the highest pneumo-
coccal death rates in this population were due to
pneumonia [8].
In Europe, the annual incidence of CAP per 1000 adults has
been reported to be 10.8 in Finland, 4.1 in the UK and
between 3.7 and 10.1 in Germany [9]. Mortality was reported
to be about 4% in outpatients and between 10% and 20% in
hospitalized patients. The mortality rate is highest among
patients admitted to intensive care units, ranging from 11.1%
to 48%, and among older patients [10].
Populations around the world are rapidly ageing, which is a
demographic indicator of improving global health. The World
Health Organisation (WHO) has estimated that the world’s
population of people 60 years of age and older has doubled
since 1980 and is forecast to reach 2 billion by 2050 [11]. The
WHO projected that hospitalization for pneumococcal pneu-
monia will increase by 96% and that the total costs for
pneumococcal pneumonia will double from $2.5 billion to $5.0
billion [12].
Another model estimated that in the USA, in 91.5 million
adults aged ≥50 years, each year there are 29 000 cases of IPD
(27 700 cases of bacteraemia and 1800 cases of meningitis),
502 600 cases of non-bacteraemic pneumococcal pneumonia
(198 600 cases requiring hospital care and 304 000 cases
treated outside the hospital setting) and 25 400 deaths
associated with pneumococcal disease (6200 due to invasive
disease and 19 200 due to pneumonia) [13]. This important
clinical burden was estimated to cost $ 3.7 billion and $ 1.8
billion in annual direct and indirect costs, with non-bacterae-
mic pneumococcal pneumonia accounting for most of these
(81% of direct costs and 62% of indirect costs). Individuals
suffering from chronic disease or immunosuppression have a
higher individual risk for IPD than healthy subjects in the same
age group; even in the presence of indirect (herd) protection;
consequently, they are at greater risk of infection and disease
than same-aged healthy subjects.
Pneumococcal Vaccine Development
The first immunotherapy for pneumococcal diseases was an
anti-pneumococcal serum discovered in 1891 and commer-
cialized in 1895 [14]. The development of a pneumococcal
vaccine started as early as 1911 when a whole cell vaccine
first became available (Table 1) [14]. In the late 1940s, the
capsules of a number of clinically important serotypes were
purified and multivalent plain polysaccharide vaccines became
available. In the USA, a 14-valent and then a 23-valent
polysaccharide vaccine were registered in 1977 and 1983,
respectively. The 23-valent plain polysaccharide (PPV23)
vaccine is licensed for administration from the age of
2 years. However, plain polysaccharide vaccines are poorly
immunogenic in infants. This limitation has been overcome
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with the development of conjugate vaccine technology,
which has since been applied to a number of vaccine-pre-
ventable disease targets.
The first pneumococcal conjugate vaccine (hepta-valent
pneumococcal conjugate, PCV7, conjugated to the CRM197
carrier protein) was registered for use in children in 2000 in
the USA and in 2001 in Europe. Since 2010, higher-order
conjugates, a 10-valent PCV (PCV10, conjugated to protein D,
diphtheria toxoid and tetanus toxoid carrier proteins) and a
13-valent PCV (PCV13, conjugated to CRM197 carrier pro-
tein) have been licensed. In addition to the paediatric
indication, PCV13 has now been licensed in Europe for active
immunization for the prevention of invasive disease caused by
S. pneumoniae in adults aged ≥50 years and in the USA for the
prevention of pneumonia and IPD in adults aged ≥50 years old
[15,16]. In adults, the protective antibody threshold is not
known, so in all the pivotal clinical trials, a serotype-specific
opsonophagocytosis assay (OPA), which measures functional
antibody concentrations, was used as a surrogate to assess
potential efficacy against invasive pneumococcal disease (IPD)
and pneumonia. OPA geometric mean titres measured
1 month after each vaccination were calculated. The pivotal
trials for Prevenar 13 were designed to show that functional
OPA antibody responses for the 13 serotypes were non-infe-
rior, and for some serotypes were superior, to the 12
serotypes in common with the licensed 23-valent pneumo-
coccal polysaccharide vaccine (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C,
19A, 14, 19F, 23F) 1 month after vaccine administration. The
response to serotype 6A, which is unique to Prevenar 13, was
assessed by demonstration of a four-fold increase in the
specific OPA titre above pre-vaccination levels [17].
Mechanisms of Action for Polysaccharide
and Conjugate Vaccines
Streptococcus pneumoniae are polysaccharide-encapsulated,
lancet-shaped, gram-positive, facultative-anaerobic organisms.
Both the plain polysaccharide and the polysaccharide conjugate
vaccines rely on the capsular polysaccharide antigen to induce
a serotype-specific immune response. However, vaccines
containing plain polysaccharide have a different mechanism of
action from those containing polysaccharide conjugated to a
carrier protein [18]. The plain polysaccharides are T-cell-inde-
pendent antigens that simulate immediate B-cell responses by
cross-linking the B-cell receptors. This results in B-cell
differentiation to plasma cells that can then produce antibod-
ies. The process does not lead to an expansion of sero-
type-specific B cells, or to the creation of serotype-specific
memory B cells. In contrast, conjugated vaccines elicit a
T-cell-dependent response. The polysaccharide antigens bind
to specific naive B cells, but as the carrier protein is also
processed within the B-cell, the peptides produced are
presented (via MHC class II molecules) to carrier-peptide-spe-
cific helper T cells. The helper T cells are themselves primed
to the peptides through interaction with antigen-presenting
cells that have also processed the carrier protein [19]. This
helper T-cell process therefore enhances the immune
response provided by the B cells, so that the antibody
response is of greater specificity and functionality. Memory B
cells are also induced, which enables an anamnestic response
to be elicited after a subsequent dose of the vaccine or enables
a booster response on exposure to the antigen during natural
infection.
The Impact of Childhood PCV7 Vaccination
It is over 10 years since PCV7 was introduced into the US
national vaccination programme. PCV7 has been licensed in
nearly 100 countries, and included in many national vaccination
programmes as either a 3 + 1 (three doses under 6 months
plus a booster after 1 year of age), a 2 + 1 (two doses under
6 months plus a booster after 1 year of age) or a 3 + 0 (three
doses before 1 year of age) dose schedule for immunizing
children during the first 2 years of life [20]. A summary of
schedules in the 27 European Union countries and the four
European Free Trade Area countries is given in Table 2
TABLE 1. The development of pneumococcal immunotherapy and vaccines [14]
Serum therapy 1891 (and was commercially available in 1895)
Whole cell vaccine 1911
Purified capsular vaccine Mid 1930s: multivalent purified capsular vacine
Plain polysaccharide vaccines Late 1940s: multivalent polysaccharide vaccine
Early 1950s: first-generation pneumococcal polysaccharide vaccines on the market
1977: 14-valent (1, 2, 3, 4, 5, 6A, 7F, 8, 9N, 12F, 18C, 19F, 23F, 25F) vaccine registered in the USA
1980s: 17-valent (1, 2, 3, 4, 6A, 7F, 8, 9N, 11A, 12F, 14, 15F, 17F, 18C, 19F, 23F, 25) registered in Europe
1983: 23-valent (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 11F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F)
vaccine registered in the USA
Conjugated polysaccharide vaccines 2000: hepta-valent vaccine (PCV-7) (4, 6B, 9V, 14, 18C, 19F, 23F) registered in 2000 in the USA and in 2001 in Europe
2009: 10-valent (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) vaccine registered
2010: 13-valent (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) vaccine registered
Investigational vaccines Protein vaccines, containing specific pneumococcal proteins, such as pneumolysin, choline-binding proteins (PspA, PspC and Lyt A)
and lipoproteins (PsaA)
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[21,22]. Since its introduction into childhood vaccination
programmes, PCV7 has dramatically reduced the incidence
of VST-IPD (IPD due to vaccine serotypes) [23]. For example,
following the introduction of PCV7 in the USA in 2000, a 100%
reduction in VST-IPD in children <5 years was established by
2007. The incidence of all-type IPD in children <5 years was
reduced by 76%, from 98.7 cases per 100 000, before PCV7
introduction, to 23.6 cases per 100 000 afterwards [5].
Although both were highly significant, there was a greater
reduction in the incidence of outpatient IPD compared with
that of hospitalized IPD; 85.4% (from 67.3 cases per 100 000
to 9.8 cases per 100 000) versus 59.9% (from 31.4 cases per
100 000 to 12.6 cases per 100 000) [5]. In this study the
incidence of meningitis was reported to be significantly
reduced by 63.8% (from 4.7 cases per 100 000 to 1.7 cases
per 100 000). Similar trends were observed in various
European countries, with a 97% reduction of VST-IPD in
children <5 years of age in Belgium between 2002 and 2009
[24], a more than 90% VST-IPD reduction in children <2 years
in 2010 in Germany [25], and 90% and 95% reductions in
VST-IPD in the Netherlands and Norway, respectively [26,27].
In addition, PCV7 vaccination of children also had an impact
on non-invasive presentations of pneumococcal disease. For
example, in the UK, hospitalizations for bacterial pneumonia
and empyaema were reduced by 19% and 22%, respectively,
2 years after PCV7 implementation [28]. A retrospective
interrupted time-series analysis of data from a large healthcare
database in the USA (Nationwide Inpatient Sample) showed a
39% decrease in all-cause pneumonia hospital admission for
children aged <2 years from before PCV7 introduction (1997–
99) to after its introduction (2001–04) [29].
In the background of substantial PCV7 supply shortages in
2001–03 and 2004, a step-wise reduction was reported in a
retrospective study of acute otitis media visits in a private,
non-profit health plan in the Boston area (Harvard Vanguard
Medical Associates) that analysed data for children aged
2 months to 12 years between 1996 and 2004 [30,31]. In this
study there had been a reduction between the years 1996 and
1997 and the years 2001 and 2002, as the American Academy
of Pediatrics and the CDC working group on acute otitis
media guidelines published in 1999 recommendations for
high-dose amoxicillin in children <2 years with uncomplicated
otitis media and annual use of high-dose amoxicillin for the
treatment of uncomplicated acute otitis media increased
rapidly in the study setting between 1998 and 2000 [32].
There was another discrete step-wise fall in uncomplicated
acute otitis media incidence between 2002 and 2004 [33].
Another retrospective analysis of a US insurance database
(self-insured employers, including large private employers and
state governments) in the USA (MarketScan) showed a 43%
and 42% reduction in acute otitis media-related ambulatory
visits and acute otitis media-related antibiotic prescriptions for
children aged <2 years, respectively, comparing 2004 with the
baseline 1997–99 [33], which was most marked between 2001
and 2002, followed by a linear decline from 2002 to 2004.
In Greece, in an observational hospital-based study con-
ducted over an 8-year period in children aged <14 years, the
rates of otorrhoea visits per 10 000 emergency department
visits was reduced by 38%, from 133 to 83, mainly through a
reduction in the incidence of pneumococcal disease (48%
decrease, from 25 to 13 per 10 000 emergency department
visits) [34]. A similar impact on complicated otitis media has
been reported in Italy and Sweden [35,36].
The impact on pneumococcal disease depends on the
clinical presentation being measured, (Fig. 1). It is important to
remember that a clinical presentation can be due to viral as
well as bacterial infections. In addition, the disease can be
caused by bacteria other than S. pneumoniae. Among disease
caused by S. pneumoniae, vaccine serotypes account for a
proportion that may depend on the particular clinical presen-
tation of the pneumococcal disease. Consequently, the
observed effectiveness of pneumococcal vaccination depends
on the relative fraction of disease caused by vaccine serotype
S. pneumoniae, the efficacy of PCV7 against vaccine serotype
TABLE 2. Overview of pneumococcal conjugate vaccine
(PCV) programmes in European Union and European Free
Trade Area countries in 2013 (based on [22])
Country
Year introduced
into programmea
Current
schedule
Austria 2012 2+1
Belgium 2007 2+1
Bulgaria 2010 3+1
Cyprus 2008 2+1
Czech Republic 2010 3+0
Denmark 2007 2+1
Estonia Not in national immunization programme
Finland 2010 2+1
France 2006 2+1
Germany 2006 3+1
Greece 2006 3+1
Hungary 2008 2+1
Iceland 2011 2+1
Ireland 2008 2+1
Italy 2006 2+1
Latvia 2010 2+1
Lithuania Not in national immunization programme
Luxembourg 2003 2+1
Malta Not in national immunization programme
Netherlands 2006 3+1
Norway 2006 2+1
Poland 2010 3+1
Portugal Not in national immunization programme
Romania Not in national immunization programme
Slovakia 2009 2+1
Slovenia 2011 3+1
Spain 2008 3+1
Sweden 2009 2+1
Switzerland 2006 2+1
United Kingdom 2006 2+1
aNational except Italy, Spain and Sweden, where the introduction was regional and
Poland and Slovenia where the vaccine is recommended for high-risk groups.
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S. pneumoniae, the proportion of vaccine serotype
pneumococcal supra-infections complicating a respiratory viral
infection that can be avoided in pneumococcal conjugate
vaccine immunized children [37], and the indirect (herd)
impact from a generalized national immunization programme
with PCV7 that can reduce the likelihood of transmission
within the community.
Herd Effect and Replacement Disease
PCV7 has also been shown to reduce asymptomatic nasopha-
ryngeal carriage (NPC) of S. pneumoniae, which is a source for
subsequent disease in the colonized person or of transmission
to other susceptible individuals in the community. In 2009 in
the Netherlands, 3 years after PCV7 had been introduced into
the national immunization programmes, nasopharyngeal swabs
were examined for pneumococcal carriage from three
cohorts: healthy 11-month-old children who had received
the three primary vaccinations; healthy 24-month-old children
who had received also the final (booster) dose; and one parent
of the older children. These were compared with historical
control samples from a longitudinal randomised controlled
trial that recruited 6-week-old children from July 2005 to
February 2006 [38]. With respect to the vaccine serotypes, in
the 11-month-old children there was an 86% (95% CI 77–91)
reduction of VST-NPC, in 24-month old children (fully
vaccinated) there was a 92% (95% CI 85–95) reduction, and
in parents there was a 94% (95% CI 74–99) reduction. In
another study, nasopharyngeal swabs were collected from
consenting children ≤4 years old attending a paediatric outpa-
tients department in a large UK teaching hospital from
October to February in 2006/7, 2007/8 and 2008/9 [39]. The
results showed that, 2 years after the introduction of PCV7 in
September 2006, there was a decrease in NPC of vaccine
serotypes, particularly 6B (from 23.2 to 3.9%), 19F (from 13.5
to 1.0%) and 23F (from 8.7 to 2.9%). This was accompanied by
an increase in the carriage of non-vaccine serotypes, partic-
ularly 19A (from 2.9 to 6.9%) and 6C (from 3.8 to 13.7%). In
the Liguria Region in Italy, serotype 19A also emerged as a
predominant non-vaccine serotype in NPC of children aged
<5 years, over a 7-year period of vaccination with PCV7 that
had very high uptake in the last 4 years [40]. This phenomenon
has also been reported in the Netherlands in a randomized
controlled study and has been the subject of a literature
review of observational studies [41,42].
PCV7 infant vaccination programmes have been shown to
induce an indirect (herd) protection; for example, there was a
reduction in vaccine-serotype IPD in the over 65-year-old
population in the UK seen concurrently with the reduction in
VST-IPD in the under 5-year-old population [43]. A reduction
of VST-IPD in all ages has been reported in two studies from
Australia, six studies from Europe and two studies from the
USA [5,26,43–50]. The reported reduction values range from
1.4% in the Netherlands to 93.5% in the USA, [5,26]. The
smallest all-age group reduction (1.4%) was reported for a
period up to 2 years after the introduction of PCV in the
national immunization programme in the Netherlands, but in
another study reporting data up to 4 years after PCV7
introduction in the Netherlands the reduction was reported
to be 53.6% (from 6.9 case per 100 000 to 3.2 cases per
100 000) [26,50]. This illustrates the importance of knowing
how long after vaccine introduction the assessment is carried
out.
However, while reducing vaccine-serotype disease, an
important secondary effect of the PCV7 vaccination pro-
gramme was found to be that of replacement disease caused by
non-vaccine serotypes. In the UK, a significant rise in the
incidence of IPD caused by serotypes 7F, 19A and 22F has
been reported [25]. In the USA, an increase in disease caused
by antibiotic-resistant serotype 19A was reported [24,39]. In a
review of data on serotype replacement in disease after PCV7
vaccination it was reported that although in most populations
there has been an increase in non-VST-IPD, in most cases this
increase has been less than the reduction in VST-IPD, so
resulting in a net reduction in all-type IPD [51]. The authors
FIG. 1. Schematic representation of how, for a given type of clinical
presentation, the fraction attributable to bacteria, Streptococcus
pneumoniae and vaccine serotypes may vary. This phenomenon can
explain how the impact on the different clinical presentations can vary
also.
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suggest that the serotype replacement in nasopharyngeal
carriage does not lead to a comparable serotype replacement
in disease because of the lower invasiveness of the replacing
serotypes in the nasopharynx. In comparing the incidence of
IPD in the pre-vaccination and post-vaccination periods,
disease surveillance systems must consistently note the source
of clinical isolates (i.e. proportion of IPD from blood cultures
of febrile children), be aware of changes in the frequency of
IPD detection and reporting over time (i.e. active compared
with passive reporting systems) and natural fluctuations in
serotype-specific IPD incidence, obtain a sufficiently long
period of follow-up, and follow the presence of immunode-
ficiencies and other co-morbidities with the clinical isolate.
Furthermore, measured impact can depend upon vaccine
uptake, include the rate of uptake and regional differences in
vaccine uptake, as well as patterns of antibiotic use [51].
Impact of Childhood PCV13 Vaccination
PCV13 has been introduced into national immunization
programmes since 2010, and surveillance demonstrates that
this vaccine has an additional impact, targeting the serotypes
unique to PCV13, as well as continuing to protect against the
PCV7 serotypes. In the UK, PCV13 was introduced nationwide
in transition from PCV7 (i.e. as the next vaccine for any dose in
the paediatric pneumococcal conjugate vaccination schedule);
however, there was no catch-up vaccination programme for
older children who were already fully vaccinated with PCV7.
The first published data from the UK, covering the transition
period between the two vaccines, showed that among the 166
IPD cases in PCV13-eligible children reported by July 2011, the
vaccine effectiveness was 78% (95% CI 18–96) for two doses
administered to children aged <12 months and 73% (95% CI
29–90) for one dose (aged ≥12 months) [52]. Importantly, IPD
caused by the PCV7 non-vaccine serotypes 7F and 19A has
been offset, as the vaccine effectiveness for at least one dose
for 19A and 7F IPD was 70% (95% CI 10–90) and 76% (95% CI
21–93), respectively. Active surveillance of both carried
pneumococci in young children and the serotypes causing
IPD is critical to inform new vaccine development and national
immunization policies.
Remaining Burden of IPD
The burden of IPD has been substantially reduced due to the
impact of PCV7 on the incidence of VST-IPD, and the
remaining disease burden can be accounted for, to a large
extent, by the serotypes targeted by the higher-order
pneumococcal conjugate vaccines [5,53–55]. With the wide-
spread introduction of PCV13 we can expect to see further
reductions in the incidence of IPD through the non-PCV7
serotypes present in PCV13.
Even after the introduction of paediatric PCV programmes,
the incidence of IPD still has a characteristic U-shaped
distribution, with the incidence being higher in children
<5 years, then decreasing in older children, adolescents and
young adults and finally increasing again in those aged >45–
50 years, although the incidence at the two extremes of age
has decreased. Data from a passive surveillance system in
Europe, which probably underestimates the disease burden,
showed that in 2009, the highest incidence of IPD was
reported for those aged 65+ (9.84 per 100 000) and the next
highest was in children <5 years (6.57 per 100 000) [4]. In
2009, in the USA the rate of IPD (per 100 000) was greatest in
children under 5 (<1 year: 34.2; 1 year: 26.6; 2–4 years: 13.1)
and in adults aged 50+ (50–64 years: 18.8; 65+: 36.4) [3]. As
childhood immunization with PCV7 has had an impact (both
direct and indirect) on the burden of invasive disease across a
number of age groups, it is now anticipated that PCV13 will be
effective against all PCV13 vaccine-serotype serotypes in
non-immunized age groups as has been seen for PCV7
vaccine-serotype disease.
What Can We Expect from Vaccinating
Adults with PCV13?
In October 2011 PCV13 was approved for active immunization
for the prevention of invasive disease caused by S. pneumoniae
in adults aged 50 years and older in Europe. On December 30,
2011, under their accelerated approval regulation, the FDA
approved PCV13 for prevention of pneumonia and invasive
disease caused by PCV13 serotypes among adults aged
50 years and older.
The clinical trials for the licensure of PCV13 in children
used a correlate of protection established by the WHO, an
‘immunogenicity bridge’ for paediatric licensure based on an
IgG threshold of 0.35 lg/mL, with an outcome of non-infe-
riority of the immune response, compared with PCV7,
assessed after the primary series [21]. For the clinical trials
with PCV13 in adults, a serotype-specific OPA was used as an
immunological basis for licensure, as compared with the
licensed 23-valent pneumococcal polysaccharide vaccine
PPV23 vaccine. OPA geometric mean titres (GMTs) are
expressed as the reciprocal of the highest serum dilution that
reduces survival of the pneumococci by at least 50%. Pivotal
clinical trials for PCV13 demonstrated the non-inferiority of
functional OPA antibody responses 1-month after vaccination
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for the 12 serotypes that are common with PPV23 (1, 3, 4, 5,
6B, 7F, 9V, 14, 18C, 19A, 19F, 23F). The response to serotype
6A, which is unique to PCV13, was assessed by demonstrating
a four-fold increase from pre-vaccination levels in the specific
OPA titre.
As part of the accelerated approval regulation, a post-licen-
sure, randomized, placebo-controlled clinical trial is currently
underway in the Netherlands to assess the efficacy of PCV13
in the prevention of a first episode of VST pneumococcal CAP
in community-dwelling adults aged ≥65 years [56]. Although
not part of the clinical programme for PCV13 in adults,
PCV7 efficacy in immunocompromised subjects has been
demonstrated in a double-blind, randomized (1 : 1),
placebo-controlled clinical efficacy trial in Malawi in a popu-
lation (n = 496) who had recovered from documented IPD
and that included 88% HIV-infected individuals. They received
two doses of PCV7 given 4 weeks apart [57]. A vaccine
efficacy of 74% (95% CI 30–90) was reported against a further
episode of pneumococcal infection by VST serotypes or
serotype 6A among HIV-infected subjects [and, for all subjects,
there was an efficacy of 73% (95% CI 23–89)]. In a subgroup of
220 patients who were severely immunocompromised (CD4+
cell count <200 cells/mm3 at baseline), the vaccine efficacy was
86% (95% CI 41–97).
The plain polysaccharide vaccine, PPV23, is effective against
IPD in younger adults, although efficacy in elderly subjects or
in those with underlying co-morbidities, the duration of
protection and guidelines for revaccination, and the impact
on all-cause pneumonia have not been clearly established
[58,59]. The immunogenicity and safety of PCV13 have been
demonstrated in adults aged 50 years and older, including
those previously vaccinated with a pneumococcal polysac-
charide vaccine [17]. PCV13 may be administered concom-
itantly with the seasonal trivalent inactivated influenza
vaccine. Regardless of previous pneumococcal vaccination
status, if the use of 23-valent polysaccharide is considered
appropriate, PCV13 should be given first [17]. PCV13 induces
an immune response that is associated with immunological
memory, while plain polysaccharide vaccine does not. In
subjects aged 60–64 years, the duration of the immunological
memory provided by PCV13 has been demonstrated at 3–
4 years after primary vaccination, based on response to
revaccination with PCV13 or subsequent vaccination with
PPV23 [17].
Conclusions
The burden of pneumococcal disease remains high, despite
effective childhood vaccination with PCVs. In 2008 the WHO
stated: ‘there is a need for more efficacious conjugated
vaccines or other types of vaccines covering the majority of
the pneumococcal serotypes that cause serious disease in
older children and adults worldwide and that frequently are
also responsible for resistance to commonly used antimicrobial
drugs. WHO supports the ongoing efforts to develop such
products’ [40,60,61]. Since the elderly population remains at
risk, the growing elderly population throughout the world will
therefore amplify the burden. Although effective antibiotics are
available, global mortality rates attributable to S. pneumoniae
disease have not changed significantly over many decades.
Novel immunization strategies remain the only practical means
to reduce significantly the global mortality and morbidity due
to S. pneumoniae in adults.
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